0002046386-26-000009
SEC filingNet sales grew 11.5% to $28.4B, but gross margin compressed due to tariffs; net income slightly down.
Medline Inc. is the largest provider of medical-surgical (med-surg) products and supply chain solutions, serving all points of care from hospitals to post-acute facilities. Founded in 1966, the company operates through two reportable segments: Medline Brand and Supply Chain Solutions, supported by its Prime Vendor model, differentiated distribution network, and robust commercial platform.
The Medline Brand segment offers approximately 190,000 med-surg products organized into three categories: Front Line Care (wound care, gloves, skin care, etc.), Surgical Solutions (surgical trays, drapes, instruments, orthopedic implants), and Laboratory and Diagnostics (point-of-care testing, analyzers, consumables). The Supply Chain Solutions segment provides approximately 145,000 products from over 1,300 third-party suppliers, along with consulting, outsourced warehouse management, and other optimization services. The company does not disclose revenue share by segment.
Medline’s comprehensive product portfolio includes surgical and procedural kits, gloves, protective apparel, urological and incontinence care, wound care, and lab/diagnostics products. Key brands include Medline, Curad, Microtek, Hudson, and Proxima. The Prime Vendor model—multi-year distribution agreements typically with five-year terms—is central to its go-to-market strategy, driving a >98% average retention rate over the past five years.
The company reaches customers through a U.S. commercial team of approximately 4,000 people, including account managers, product specialists, and clinical resources. Prime Vendor relationships consolidate a customer’s med-surg purchasing with Medline, providing cost savings and incentivizing conversion to Medline Brand products. Distribution is enabled by 70 global centers (45 in the U.S.), a fleet of over 2,100 MedTrans trucks, and next-day delivery to 95% of U.S. customers. International sales are de minimis, with no single international market exceeding 3% of net sales.
Medline competes with both med-surg product manufacturers and distributors. Named competitors include McKesson, Cardinal Health, Owens & Minor, and Henry Schein. The company believes its vertical integration and commercial excellence provide superior cost savings and holistic solutions compared to rivals that rely on third-party distributors or lack similar scale.
The company’s strategy centers on expanding Prime Vendor relationships, converting third-party product purchases to higher-margin Medline Brand products, leveraging its manufacturing capabilities (producing about one-third of Medline Brand products in 30 facilities), continuous innovation (2,300+ patents, 250+ new products in three years), and utilizing approximately 25% incremental distribution capacity to support long-term growth.
As of December 31, 2025, Medline employed over 45,000 people worldwide, over 26,000 in the U.S. None of its U.S. employees are unionized. The company focuses on talent attraction, development, engagement, and inclusion, with comprehensive training programs and employee resource groups.
For the year ended December 31, 2025, Medline generated net sales of $28.4 billion, an increase of 11.5% compared to $25.5 billion in the prior year. The growth was driven by a 10.5% organic volume increase and 0.9% from acquisitions, with pricing having an immaterial impact. Gross profit rose 7.8% to $7.5 billion, but gross margin contracted from 27.3% to 26.4%, primarily due to 115 basis points of headwinds from higher import costs related to tariffs. Operating income grew 3.1% to $2.2 billion, as SG&A expenses increased 10.1% due to higher compensation, distribution, and acquisition-related costs. Net income decreased 3.6% to $1.2 billion, reflecting higher interest expense, foreign exchange losses, and a higher tax provision. Adjusted EBITDA, a non-GAAP measure, increased 3.2% to $3.5 billion, with Adjusted EBITDA margin declining from 13.2% to 12.2%.
Medline Brand segment net sales increased 9.6% to $13.7 billion, driven by volume growth in Prime Vendor products and $221 million from acquisitions. Segment Adjusted EBITDA margin fell from 26.1% to 24.3%, with 235 basis points of tariff headwinds partially offset by 47 basis points of lower freight costs. Supply Chain Solutions segment net sales rose 13.2% to $14.7 billion, supported by new and existing Prime Vendor relationships. Segment Adjusted EBITDA margin improved from 5.0% to 5.5%, benefiting from operating leverage on higher volumes. The mix shift continues toward Supply Chain Solutions, which now represents 51.7% of total net sales.
Management provided discrete guidance on two key items. For fiscal 2026, the company estimates an incremental net adverse impact of approximately $200 million to income before taxes from tariffs and tariff developments, based on the latest policies in effect as of December 31, 2025. Capital expenditures are anticipated to be approximately $500 million, primarily for expanding manufacturing facilities and distribution centers and further automation investments. Additionally, the company expects to continue benefiting from Prime Vendor growth, Medline Brand conversion opportunities, and strategic M&A. The IPO completed in December 2025 strengthened the balance sheet, with net proceeds of $7.0 billion used to repay debt and redeem equity, positioning Medline for future investments and shareholder returns.
As of December 31, 2025, Medline's cash and cash equivalents surged to $1.94 billion from $199 million in the prior year, driven by IPO proceeds of $7.0 billion. Total debt stood at $12.6 billion (face value $12.8 billion), a decrease of $4.2 billion from $16.8 billion in 2024. The debt reduction was achieved by using IPO proceeds to repay $3.3 billion of Dollar Term Loans and all outstanding Euro Term Loans ($730 million). The remaining debt consists of $8.5 billion in fixed-rate notes (3.875%, 5.25%, and 6.25%) and $4.3 billion in variable-rate term loans. The revolving credit facility of $1.0 billion remained undrawn, with $947 million available after letters of credit.
Medline disclosed $849 million in unconditional purchase obligations as of December 31, 2025. These are legally binding agreements to purchase goods or services, with payments due as follows: $172 million in 2026, $162 million in 2027, $169 million in 2028, $172 million in 2029, $115 million in 2030, and $59 million thereafter. Additionally, the company has operating lease obligations of $591 million (undiscounted) and $312 million in future lease payments for warehouse facilities not yet commenced. The tax receivable agreement (TRA) liability of $3.5 billion represents a significant non-current obligation, contingent on future tax benefits.
Medline's capital allocation in 2025 was heavily influenced by the IPO. The company used $5.1 billion of IPO proceeds to repay debt and $1.97 billion to purchase Class A common stock and redeem Common Units from pre-IPO owners. No quarterly dividends were declared. Capital expenditures totaled $447 million, or 1.6% of net sales ($28.4 billion), compared to $354 million in 2024. The company did not announce any new share repurchase authorization; the buyback was a one-time transaction. Debt issuance included $7.6 billion in new borrowings during 2025, primarily to refinance existing facilities, alongside $11.7 billion in repayments.
The Notes to Financial Statements do not include a separate segment disclosure footnote. As per Note 5, the company reorganized into two reportable segments in 2024: Medline Brand and Supply Chain Solutions. Goodwill allocation was $6.7 billion to Medline Brand and $1.4 billion to Supply Chain Solutions. However, no revenue or operating income details by segment were provided in the Notes. Geographic revenue breakdown is not explicitly disclosed in the Notes; net sales are generated primarily in the United States, with international operations in Canada, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. The income tax note indicates $929 million of U.S. pre-tax income and $319 million international for 2025.
The provided document excerpt contains the audit report and notes but does not include the actual cash flow statement figures. Therefore, a cash flow analysis cannot be performed.